What Is the Lowest Dose of Progesterone for HRT? Microdosing Guide

Why Progesterone Dose Matters in HRT

Progesterone in HRT serves one non-negotiable purpose for women with a uterus: it opposes the proliferative effect of estrogen on the endometrial lining. Without adequate progesterone, estrogen-only therapy raises the risk of endometrial hyperplasia and, over time, endometrial cancer. The landmark Women's Health Initiative (WHI) and the earlier PEPI trial established that adding a progestogen to estrogen therapy reduces this risk to baseline or below [1][2].

The Endometrial Protection Threshold

The PEPI trial (N=875) demonstrated that micronized progesterone at 200 mg cyclically (12 days per month) prevented endometrial hyperplasia as effectively as medroxyprogesterone acetate 10 mg [2]. That 200 mg cyclic dose became the FDA-approved regimen for Prometrium when used with conjugated estrogens. A lower continuous dose of 100 mg nightly has also shown endometrial safety in observational data spanning up to 5 years, according to findings published in Climacteric [3].

When Clinicians Consider Going Lower

Not every woman tolerates standard doses well. Side effects like bloating, breast tenderness, mood changes, and daytime sedation prompt some prescribers to explore doses below 100 mg. The clinical question is straightforward: can you reduce progesterone enough to minimize side effects while still protecting the uterus?

The answer depends on estrogen dose, the route of progesterone delivery, and how closely the patient is monitored. A woman on low-dose transdermal estradiol (0.025 mg/day) may need less endometrial opposition than one on 0.1 mg/day [4].

Standard Progesterone Doses in HRT

Before discussing microdosing, it helps to anchor against the well-studied doses. The following represent the most commonly prescribed progesterone regimens in menopausal HRT.

Cyclic Oral Regimens

The classic cyclic protocol calls for 200 mg oral micronized progesterone (OMP) at bedtime for 12 to 14 days of each calendar month. This produces a withdrawal bleed and has the strongest endometrial safety data from the PEPI trial [2]. The Endocrine Society's 2015 clinical practice guideline on menopausal HRT lists cyclic OMP 200 mg as a first-line progestogen option [5].

Continuous Oral Regimens

For women who prefer no monthly bleeding (typically those more than 1 to 2 years postmenopausal), continuous OMP at 100 mg nightly is widely used. The E3N French cohort study (N=80,377) found that women using estrogen combined with micronized progesterone had no significant increase in breast cancer risk over a mean follow-up of 8.1 years, a finding that has driven preference for micronized progesterone over synthetic progestins [6].

Vaginal Progesterone

Vaginal administration delivers higher local uterine concentrations at lower systemic doses. A 2005 study by de Ziegler et al. Showed that vaginal progesterone 45 mg gel (Crinone 4%) achieved endometrial secretory transformation comparable to 200 mg oral, with plasma progesterone levels roughly one-fifth as high [7]. This route may offer a path to lower total body exposure while maintaining uterine protection.

What Does Progesterone Microdosing Actually Mean?

Microdosing in this context refers to using progesterone at doses below the standard 100 mg continuous or 200 mg cyclic thresholds. There is no formal clinical definition. Prescribers who use the term typically mean doses in the 25 to 50 mg oral range or equivalent topical/vaginal preparations.

The Clinical Logic Behind Microdosing

The rationale rests on two observations. First, side effects from progesterone (sedation, mood disruption, bloating) are dose-dependent [8]. Second, women on very low estrogen doses may not require the same level of endometrial opposition as those on standard or high-dose estrogen.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and a principal WHI investigator, has noted: "The goal is to use the lowest effective dose of both estrogen and progestogen for the shortest duration consistent with treatment goals" [9]. That principle, articulated in the 2017 North American Menopause Society (NAMS) position statement, supports individualized dose-finding rather than one-size-fits-all prescribing.

Doses Reported in Clinical Practice

Some practitioners report prescribing the following microdose regimens:

• 50 mg oral micronized progesterone nightly, continuous
• 25 mg oral micronized progesterone nightly, continuous
• 20 mg topical progesterone cream (equivalent to roughly 20 to 40 mg absorbed, though absorption varies widely by product)
• Compounded vaginal progesterone suppositories at 25 to 50 mg

These doses are off-label. No large randomized trial has confirmed endometrial safety at oral doses below 100 mg in women taking systemic estrogen.

Evidence for Low-Dose and Microdose Progesterone

The published data on sub-100 mg progesterone dosing in HRT is limited but growing. Here is what exists.

Oral Micronized Progesterone Below 100 mg

A small Italian study published in Maturitas (N=40) evaluated 50 mg OMP continuous combined with transdermal estradiol 25 mcg/day [10]. After 12 months, endometrial thickness remained below 5 mm in all participants, and no cases of hyperplasia were found on biopsy. The study size limits the strength of this conclusion, but it provides preliminary safety data for the 50 mg continuous dose when paired with low-dose estrogen.

A separate retrospective chart review from a UK menopause clinic (N=120) found that women on transdermal estradiol 0.025 to 0.05 mg/day combined with OMP 100 mg every other night (effectively averaging 50 mg/day) had endometrial thickness measurements comparable to those on nightly 100 mg at 12-month follow-up [11]. No hyperplasia cases were identified. Prospective trials are still needed.

Vaginal and Topical Routes at Low Doses

The vaginal route is better studied at reduced doses because of its first-pass uterine effect. A 2012 Cochrane review of progesterone for endometrial protection concluded that vaginal progesterone could achieve endometrial safety at lower systemic exposures, though the reviewers noted high heterogeneity across included studies [12].

Over-the-counter progesterone creams typically deliver 15 to 25 mg per application. The 2022 NAMS position statement specifically warns against relying on OTC topical progesterone for endometrial protection, stating that "available data are insufficient to confirm that topical progesterone creams provide reliable endometrial protection" [13]. This warning applies regardless of dose.

The Breast Cancer Angle

The E3N cohort data suggest that micronized progesterone carries a more favorable breast safety profile than synthetic progestins [6]. The relative risk for breast cancer with estrogen plus micronized progesterone was 1.00 (95% CI 0.83 to 1.22) over a mean 8.1 years of follow-up, compared to 1.69 (95% CI 1.50 to 1.91) for estrogen plus synthetic progestins. Lower doses could theoretically reduce breast tissue exposure even further, though no trial has tested this hypothesis directly.

Who Might Be a Candidate for Progesterone Microdosing?

Not everyone should attempt low-dose progesterone. The candidates who may reasonably consider it share certain characteristics.

Women on Very Low-Dose Estrogen

A woman using transdermal estradiol at 0.025 mg/day or less is exposing her endometrium to relatively modest estrogenic stimulation. The counter-dose of progesterone needed may be proportionally lower. The 2015 Endocrine Society guideline acknowledges that "lower doses of progestogens may be needed with lower doses of estrogen," though it stops short of specifying thresholds [5].

Women Who Cannot Tolerate Standard Doses

Progesterone side effects are real. At 200 mg oral, sedation is pronounced enough that bedtime dosing is standard practice. Some women experience depressed mood, anxiety, or GI discomfort even at 100 mg. For these patients, a supervised trial of 50 mg with close endometrial monitoring represents a clinical option, not a first-line recommendation.

Women Without a Uterus: A Different Calculus

Women who have had a hysterectomy do not need progesterone for endometrial protection. Some prescribers add low-dose progesterone (25 to 50 mg) for its neurosteroid effects: improved sleep, reduced anxiety, and neuroprotection. A 2020 review in Frontiers in Neuroscience detailed progesterone's action on GABA-A receptors through its metabolite allopregnanolone, which mediates sedative and anxiolytic effects at relatively low circulating levels [14].

How to Monitor Safety on a Microdose Protocol

Any regimen below standard dosing requires more attentive monitoring. The goal is to catch endometrial stimulation before it progresses.

Transvaginal Ultrasound

Endometrial thickness measurement by transvaginal ultrasound is the primary surveillance tool. An endometrial stripe of 4 mm or less in a postmenopausal woman is generally reassuring. ACOG recommends endometrial biopsy when thickness exceeds 4 mm in the setting of postmenopausal bleeding [15].

For women on microdose progesterone, a reasonable monitoring schedule includes:

• Baseline transvaginal ultrasound before starting HRT
• Repeat at 6 months
• Annual measurement thereafter if thickness remains below 4 mm
• Immediate evaluation for any unscheduled bleeding

Endometrial Biopsy

If ultrasound shows thickening above 4 mm or if breakthrough bleeding occurs, office endometrial biopsy with a Pipelle catheter is indicated. This takes roughly 60 seconds and does not require anesthesia in most cases. The sensitivity of Pipelle biopsy for detecting endometrial cancer exceeds 99% in postmenopausal women, according to a meta-analysis in BJOG [16].

Symptom Tracking

Beyond endometrial safety, patients should track sleep quality, mood, bleeding patterns, and breast tenderness. Progesterone's neurosteroid effects mean that dose reductions can worsen insomnia or anxiety in some women, creating a trade-off that must be discussed explicitly.

Practical Microdosing Protocols

The following represents the range of low-dose approaches reported in clinical practice. None are FDA-approved for HRT. All require informed consent and monitoring.

Protocol A: 50 mg OMP Continuous

Prescribe micronized progesterone 50 mg oral capsule at bedtime nightly. Pair with transdermal estradiol at 0.025 to 0.05 mg/day. Monitor endometrial thickness at baseline, 6 months, and annually. Increase to 100 mg if thickness exceeds 4 mm or bleeding occurs.

Protocol B: 100 mg OMP Alternate Nights

Some clinicians prescribe 100 mg every other night to achieve a lower average daily exposure while using a commercially available capsule strength. This avoids compounding. Monitoring schedule is the same as Protocol A.

Protocol C: Vaginal Microdose

Compounded vaginal progesterone suppositories at 25 to 50 mg nightly deliver higher uterine-to-systemic ratios. This route may offer better endometrial protection per milligram than oral administration. Compounding pharmacy quality control becomes a relevant variable; the FDA does not regulate compounded preparations with the same rigor as manufactured drugs [17].

What to Avoid

Do not rely on OTC progesterone cream as a sole progestogen in any woman taking systemic estrogen [13]. Absorption is unpredictable. Serum levels achieved are inconsistent. The 2022 NAMS statement is unambiguous on this point.

The Role of Progestogen Type: Micronized vs. Synthetic

Dose discussions must account for the fact that micronized progesterone and synthetic progestins are not interchangeable milligram-for-milligram.

Why Micronized Progesterone Is Preferred

Dr. JoAnn Pinkerton, former executive director of NAMS, has stated: "Micronized progesterone is preferred by many clinicians because of its more favorable cardiovascular and breast safety profile compared to medroxyprogesterone acetate" [18]. The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) used oral micronized progesterone 200 mg cyclically and found no adverse cardiovascular signals over 4 years of treatment in recently menopausal women [19].

Synthetic progestins like medroxyprogesterone acetate (MPA) are more potent per milligram. MPA at 2.5 mg continuous provides endometrial protection but carries different metabolic and breast risk profiles. Microdosing discussions apply almost exclusively to micronized progesterone, not synthetic progestins, because the safety margins and side-effect profiles differ.

Dydrogesterone as an Alternative

Dydrogesterone (Duphaston), a retro-isomer of progesterone available in Europe and parts of Asia, has endometrial protection data at 10 mg cyclically. It is not FDA-approved in the United States. For women with access, it offers another low-dose option with a side-effect profile distinct from OMP [20].

When Microdosing Is Not Appropriate

Certain clinical scenarios demand standard or higher progesterone doses.

Women on standard-dose or high-dose estrogen (transdermal estradiol 0.075 to 0.1 mg/day or oral conjugated estrogens 0.625 mg/day) should not use sub-100 mg progesterone without close endometrial surveillance. The proliferative stimulus is too strong.

Women with a history of endometrial hyperplasia need at minimum the standard protective dose, and many clinicians prefer continuous combined regimens at 100 mg or cyclic regimens at 200 mg [5].

Obese women face higher endogenous estrogen production from adipose aromatase activity. This additional estrogenic input means their endometrium may already be stimulated above baseline before exogenous estrogen is added. Microdosing progesterone in this population carries higher risk [15].

Perimenopause presents a particular challenge. Erratic endogenous estrogen surges mean that a fixed low-dose progesterone regimen may be inadequate during high-estrogen phases of the cycle. Cyclic progesterone at 200 mg for 12 days per month is the conventional approach in perimenopause, and reducing this dose requires case-by-case evaluation.

Bottom Line on the Lowest Progesterone Dose

The lowest well-supported progesterone dose for endometrial protection in HRT remains 100 mg oral micronized progesterone taken continuously at bedtime, paired with standard-dose estrogen. When estrogen doses are very low (transdermal estradiol 0.025 mg/day or less), limited evidence supports 50 mg continuous OMP with mandatory endometrial ultrasound surveillance at 6-month intervals. Doses below 50 mg oral have no published endometrial safety data in HRT. The vaginal route may extend the usable dose range downward due to its preferential uterine delivery, but compounded preparations lack standardized quality assurance. Any patient on a microdose protocol should have a baseline transvaginal ultrasound, a repeat at 6 months, and a clear plan to escalate the dose if endometrial thickness exceeds 4 mm.